Evidence map›Paper›PMID 42220609›Full record

ArticleMaterials today. Bio2026

Provoking disulfidptosis-enhanced mitophagy by manganese-based nanoplatform via regulating cellular energy supply and redox homeostasis.

Zhenying Diao, Bin Feng, Yanfei Fu, Youcheng Liang, Long Qiu, Jianbo Sun, Yanlei Liu, Daxiang Cui, Ting Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhenying DiaoResearch Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, PR China.
Bin FengPulmonary Nodule Diagnosis and Treatment Center, GuangZhou Chest Hosipital, GuangZhou, Guangdong, 510095, PR China.
Yanfei FuInstitute of Intelligent Health Diagnosis and Treatment, School of Automation and Intelligent Sensing, Shanghai Jiao Tong University, Shanghai, 200240, PR China.
Youcheng LiangGuangdong Laboratory of Chinese Medicine (Hengqin Laboratory), Hengqin, Guangdong Macao Deep Cooperation Zone, Guangdong, 519030, PR China.
Long QiuResearch Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, PR China.
Jianbo SunResearch Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, PR China.
Yanlei LiuResearch Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, PR China.
Daxiang CuiResearch Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, PR China.
Ting YinResearch Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming and reinforcing redox defense mechanisms in tumors remains major obstacles to oxidative stress therapies in Non-small cell lung cancer (NSCLC). To address these obstacles, we strategically targeted cystine transporter SLC7A11, which plays a central role in cellular redox homeostasis. Herein, guided by bulk RNA-sequencing (RNA-seq) analysis, we identified that concurrent activation of SLC7A11 and inhibition of glucose transporter GLUT1 synergistically delays NSCLC progression. We introduced an effective strategy to effectively target SLC7A11 and GLUT1 for synergistic chemodynamic therapy (CDT) and disulfidptosis. A RNA-seq-guided nanoplatform was constructed from manganese dioxide (HMnO

Indexed as

DisulfidptosisMetabolic regulationMitophagyRNA-SequencingSynergistic therapies

Identifiers

PMID42220609
PMCPMC13218240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.